Key Highlights
- Dr. Susan Altschuller joins as Chief Financial Officer.
- Former CFO of Cerevel Therapeutics, ImmunoGen, and leadership roles at Alexion and Bioverativ.
- Extensive background in biopharma financial leadership and strategic development.
- Dragonfly Therapeutics advancing clinical pipeline in autoimmune, oncology, and neuro-inflammatory diseases.
Source: Business Wire
Notable Quote
- “We are delighted that Susan has joined Dragonfly. Her leadership growing successful biopharma companies comes at an exciting time as Dragonfly expands our clinical pipeline in autoimmune disease, oncology, and neuro-inflammatory disease. Susan’s powerful combination of financial, clinical and development experience will help drive our mission to help patients by inventing and commercializing leading immune-engaging therapeutics.” — Bill Haney, co-founder and CEO at Dragonfly Therapeutics
SoHC's Take
The appointment of Dr. Susan Altschuller as Chief Financial Officer marks a significant enhancement in Dragonfly Therapeutics’ leadership team. With her extensive experience in financial and strategic leadership within the biopharma sector, Dr. Altschuller is well-positioned to drive Dragonfly’s ambitious clinical and commercial goals. Her track record of success at leading companies like Cerevel Therapeutics and ImmunoGen underscores her capability to navigate complex financial landscapes and foster growth. As Dragonfly Therapeutics continues to advance its innovative immune-engaging therapies, the addition of Dr. Altschuller is expected to bolster its strategic direction and operational excellence.
